Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome

Abstract

Abnormal activity of the enzyme PI3K can drive cancer growth, and mutations in a PI3K subunit can sometimes lead to non-cancerous overgrowth. A cancer drug that inhibits PI3K dramatically reduces such overgrowth.